

1 **“I’m worth saving”- A Qualitative Study of People with Alzheimer’s Disease Considering**
2 **Lecanemab Treatment**

3
4 Anna L Parks, MD (1), Ayush Thacker, BS (2), Daniel Dohan, PHD (3) Liliana A Ramirez Gomez,
5 MD (4), Christine S Ritchie, MD, MSPH (2, 5) Joanna Paladino, MD* (2, 5) and Sachin J Shah,
6 MD, MPH (2, 6)*

7
8 (1) University of Utah, Division of Hematology and Hematologic Malignancies, Salt Lake City,
9 UT, USA

10 (2) Massachusetts General Hospital, Mongan Institute Center for Aging and Serious Illness,
11 Boston, MA, USA

12 (3) University of California San Francisco, Institute for Health Policy Studies, San Francisco,
13 CA, USA,

14 (4) Massachusetts General Hospital, Memory Disorders Division, Department of Neurology,
15 Boston, MA, USA

16 (5) Massachusetts General Hospital, Division of Palliative Care and Geriatric Medicine, Boston,
17 MA, USA

18 (6) Massachusetts General Hospital, Division of General Internal Medicine, Boston, MA, USA

19
20 *Co-senior authors

21
22 Word count: 2,980

23
24 Contact

25 Anna L. Parks, MD

26 2000 Circle of Hope Drive

27 Salt Lake City, Utah 84112

28 Anna.parks@hsc.utah.edu

29 801-213-2648

30
31 Acknowledgements: Dr. Shah reports research funding from NIA (K76AG074919).

32
33 COI: The authors have no financial conflicts of interest.

34

35

36 **Key Points (75-100 words=100)**

37

38 **Question**

39 How do people with Alzheimer’s disease (AD) decide on treatment with newly available anti-
40 amyloid monoclonal antibodies?

41

42 **Findings**

43 In this qualitative analysis, people with AD considering treatment relied on multiple information
44 sources; were motivated by hope to delay cognitive decline and preserve independence; and
45 worried side effects would impair quality of life. Personality traits, family support, and trust in
46 expertise determined how they balanced these tradeoffs. People with AD wanted more
47 personalized information and to hear from others who had taken the medications.

48 **Meaning**

49 As access to treatment expands, these findings inform how clinicians can help people with AD
50 make individualized treatment decisions.

51

52 **Abstract**

53

54 **Importance**

55 People with Alzheimer’s disease (AD) now have access to disease-modifying treatment with
56 anti-amyloid monoclonal antibodies (mAbs). Their perception of risks and benefits and
57 approach to treatment decisions remain unknown.

58

59 **Objective**

60 To understand how people with early AD consider benefits and costs of anti-amyloid mAbs and
61 make decisions about treatment.

62

63 **Design**

64 Qualitative semi-structured interviews

65

66 **Setting**

67 Memory care clinics at two academic medical centers

68

69 **Participants**

70 People with biomarker or imaging-confirmed early AD referred for evaluation for treatment with
71 anti-amyloid mAbs

72

73 **Main Outcomes and Measures**

74 Themes identified through content analysis

75

76 **Results**

77 Among 22 participants, mean age was 70 years, 8 (36%) were women, 22 (100%) were White,
78 8 (36%) had less than a college degree, 11 (50%) had annual income less than \$100,000, and 6
79 (27%) lived in a rural area. The analysis revealed 3 major themes and associated subthemes: 1)
80 People with AD sought and obtained information from different sources—advocacy
81 organizations, the Internet, and clinicians; 2) hopes, expected benefits, and the existential threat
82 of dementia drove willingness and readiness to start lecanemab—hopes included more time
83 feeling like themselves and doing enjoyable activities; expected benefits included stalling
84 progression, reversing cognitive decline or cure; 3) individual traits and preferences, family
85 factors, and degree of trust in expertise influenced how people balanced risks and benefits—

86 some would accept treatment at any cost; others carefully weighed risks and burdens carefully,
87 but were motivated to pursue treatment by supportive families, insurance coverage, and trust in
88 expertise; for a few, costs decidedly outweighed their personal benefits. People with AD desired
89 more individualized information on risks and benefits and wanted to hear more from patients
90 who took the medication.

91

92 **Conclusions and Relevance**

93 Results from this qualitative analysis inform clinician, health system and policy efforts
94 to promote individualized treatment decisions for anti-amyloid mAb treatment
95 through multimodal education and outreach, evidence-based communication skills, and
96 adaptation of similar care models.

97

98 **Introduction**

99 Approval of anti-amyloid monoclonal antibodies (mAbs) is a major advance in the field of
100 Alzheimer's disease (AD). This medication class is the first potentially disease-modifying
101 therapy for people with dementia. Lecanemab, approved by the Food and Drug Administration
102 (FDA) in 2023, can slow cognitive decline in early AD by six months.¹ Donanemab was FDA-
103 approved in July 2024, and clinical trials of additional mAbs are in process.²

104
105 Alongside therapeutic optimism is growing recognition of potential tradeoffs that complicate
106 treatment decisions. Side effects include intracranial swelling (amyloid-related imaging
107 abnormalities-edema), and intracranial bleeding (amyloid-related imaging abnormalities-
108 hemorrhage [ARIA-H]).³ Certain comorbidities and medications, like anticoagulants, and
109 genotypes, like apolipoprotein E ϵ 4 (*ApoE4*), increase the ARIA-H risk.⁴ Although most ARIA is
110 asymptomatic, it can result in death and disability.⁵ How patients fare long-term remains
111 unknown. Treatment requires time expenditure, including subspecialty visits, diagnostic testing,
112 monitoring, and infusions every two-to-four weeks. And anti-amyloid mAbs are financially costly
113 for individuals and society.⁶

114
115 Many have called for shared decision-making to address the complexity of treatment
116 decisions.^{4,5,7-9} To be effective, shared decision-making requires understanding how patients
117 perceive the risks and benefits of treatment and how they approach decisions.¹⁰ In the new era
118 of anti-amyloid mAbs, our aim was to understand how people with AD weigh potential benefits
119 of treatment against costs and how they make treatment decisions.

120

121 **Methods**

122

123 **Study Design and Data Collection**

124 We conducted an exploratory qualitative study using semi-structured interviews of people with
125 AD who were referred for lecanemab evaluation between February-March 2024. A
126 multidisciplinary team developed an interview guide using the Ottawa Decision Support
127 Framework.¹¹ The guide included questions about 1) information received, 2) hopes,
128 motivations, and concerns about treatment, 3) level of certainty about starting treatment, 4)
129 factors influencing decision-making, and 5) the decision-making process. Interviews were
130 conducted remotely by Zoom or telephone by trained study personnel (A.P., A.T.). The
131 institutional review boards of participating institutions approved this study as exempt. We
132 adhered to Consolidated Criteria for Reporting Qualitative Studies (COREQ) guidance.¹²

133

134 **Setting and Participants**

135 Participants were recruited by mail and telephone from memory clinic referral centers at two
136 academic medical centers, the University of Utah and Massachusetts General Hospital.
137 Participants were English-speakers, between ages 50-90 years, with early AD confirmed by
138 amyloid on cerebrospinal fluid and/or positron-emission tomography who had been referred to
139 undergo screening for lecanemab. Interviews were conducted prior to receiving lecanemab.
140 Participants completed verbal informed consent and an online demographic questionnaire
141 before participation and received a \$50 gift card.

142

143 **Data Analysis**

144 Interviews were digitally recorded, transcribed, and de-identified. Qualitative thematic analysis
145 was performed in March-April 2024 using a stepwise approach and hybrid deductive-inductive
146 coding methods.^{13,14} The primary analytic team was comprised of AP (female physician-
147 researcher with qualitative research expertise), AT (male clinical research coordinator), and JP
148 (female researcher with serious illness communication and qualitative research expertise).

149 Coders independently coded the first five transcripts deductively using the interview guide as a
150 framework; additional codes were added inductively to create the preliminary codebook. AT, AP,
151 and JP coded the remaining transcripts and met every five interviews to discuss discrepancies,
152 resolve differences by consensus, revise codes and ensure iterative content building. The final
153 codebook was applied to all interviews. Using meetings with two additional experts (DD, SS),
154 codes were grouped to develop preliminary themes and sub-themes. Associations were
155 confirmed by the entire group to identify final themes. AP, AT, and JP reviewed transcripts
156 iteratively to assess data saturation, or when interviews were not gleaning new information, at
157 which point recruitment was stopped.^{15–17}

158

159 **Results**

160 Characteristics for the 22 participants are provided in **Table 1**. The study cohort included 12
161 (55%) people from Massachusetts General Hospital and 10 (45%) from the University of Utah.
162 Mean age was 70 years, 8 (36%) were women, and 22 (100%) were non-Hispanic White. Eight
163 (36%) had less than a college degree, 8 (50%) had annual income less than \$100,000 (6 [27%]
164 were unsure or had no income), and 6 (27%) lived rurally. A majority (12 [55%]) were ready to
165 decide on lecanemab treatment, and the remainder were evenly split between ready but
166 wanting more information (5 [23%]) and not ready (5 [23%]). A small proportion would decline (3
167 [14%]), a similar proportion needed more information (4 [18%]), and most would pursue
168 treatment (15 [68%]).

169

170 Through analysis, we identified three primary themes and associated subthemes (**Figure 1**),
171 with representative quotations in the manuscript text. **Table 2** provides additional supportive
172 quotations.

173

174 **People with AD sought and obtained information from different sources**

175 Nearly all respondents reported self-directed information gathering. In addition to the Internet
176 and media, advocacy organizations played a prominent role in disseminating information and
177 empowering patients.

178

179 *“I’ve actually gone out and sought out information on my own...I was able to connect*
180 *from the Alzheimer’s page to an article on it. And I basically printed that and then kind of*
181 *read it in its entirety so that I could highlight areas of concern for myself.” (ID5)*

182

183 Most learned about anti-amyloid mAbs from their clinicians. Some learned from primary care
184 providers—often the physician to whom they first presented with cognitive complaints—while
185 others obtained information from subspecialty providers. Level of detail conveyed by clinicians
186 varied, ranging from comprehensive to only a broad overview.

187

188 *“You can do it over at our local hospital. I don’t really know much more than that...It just*
189 *was, like, a couple of minutes or something. He just said it’d be an infusion, and so I*
190 *asked him if that was—I don’t know. He didn’t really say much.” (ID 18)*

191 A few participants experienced motivating narratives from other people with AD who had
192 received anti-amyloid mAbs. In other instances, information from family members with
193 healthcare expertise played a role.

194

195 *“...I met a gal who was a little younger than me who’s been getting the treatment and*
196 *she really feels like it’s helped her quite a bit. She’s done very well on it, so that was*
197 *another exciting thing.” (ID12)*

198 **Hopes, expected benefits, and the existential threat of dementia drive willingness and**
199 **readiness to start lecanemab**

200
201 Delaying progression of cognitive decline dominated the hopes for treatment. Some participants'
202 expectations exceeded the benefits seen in clinical trials. Several hoped for a cure, while others
203 hoped that lecanemab would reverse memory loss or completely remove amyloid from the
204 brain.

205 *"[I hope] that they'll come in in a year and say, 'We can't find any amyloid plaque— in*
206 *your brain. And that the tau tangles, or whatever they are, seem not to be there.'" (ID 9)*

207 Patient motivation to accept treatment came from the opportunities to a) gain more time feeling
208 like themselves and doing enjoyable activities; b) have a plan to fight dementia rather than
209 succumbing to the status quo; or c) preserve independence.

210
211 *"I would like to be able to live a life and be able to speak and not get wound up in my*
212 *mind.... This is the anxiety.... I'm hoping it can help not only just the hope, but it's good to*
213 *have a plan and, 'This is what I'm gonna do.' And 'I've got good people around me.' I feel*
214 *good when that happens, I have to say." (ID 8)*

215
216 Some people felt motivated knowing that they were receiving the "latest and greatest" compared
217 to existing non-pharmacologic alternatives and that they were still cognitively able to assess the
218 risks and benefits.

219
220 *"I'm, you know, cognitively up with what people are saying to me and what I can read*
221 *about or have my wife read to me about. So, I'm still pretty confident and —how do I put*
222 *this? I'm worth saving." (ID 22)*

223 Respondents also described lecanemab as a stopgap until the development of more effective
224 therapies. This was coupled with anxiety about whether receiving lecanemab would preclude
225 them from future treatments.

226 *"The other thing that comes in is if you get on something, does it preclude the something*
227 *better coming along? In the next two years you know, or whatever it is, that's better. But*
228 *because you've been on this or on this, you can't do that. I don't know how likely that is."*
229 *(ID 25)*

230 Some described feeling conflicted because they worried about tradeoffs (e.g., diminished quality
231 of life from complications). Several raised concerns that lecanemab would have side effects like
232 chemotherapy (e.g., nausea, hair loss) because both are infusions.

233
234 *"It's because, you know, I've had so much trouble with drug reactions in my life that I've*
235 *tried as best I can to stay off drugs and stay away from drugs. So, I'm real—would be*
236 *really concerned about, I'd rather have like two good years with as clear a mind as I can*
237 *have, rather than having three years, but being so affected by the drugs that I'm taking*
238 *that it wouldn't be worth the extra year." (ID 11)*

239
240 **Individual traits and preferences, family factors, degree of trust in expertise influence,**
241 **and sense of pressure or urgency influenced how people with AD balance risks and**
242 **benefits in decision-making.**

243

244 When asked to consider risks and benefits, some noted that their approach was rooted in their
245 personal tendency to “look past the negatives”, rather than the specifics of anti-amyloid mAbs.
246 For others, the perceived inevitability of decline without intervention helped them decide to
247 accept treatment at any cost.

248
249 *“What do I have to lose? Is basically the way I look at it. I mean, even if it does cause*
250 *problems for me, I’m headed that way already. I’m not—might be a different kind of*
251 *problem. I don’t care.” (ID 10)*

252 The complication of ARIA-H weighed on most participants’ minds. Although people with AD
253 wanted more information on their individual risk, they felt that bleeding risk was not high and
254 surmountable. Very few mentioned death as a potential outcome.

255
256 *“I just know that there’s things that could go bad, and I’m ready for that. I’d rather be able*
257 *to get onto the drug and... I’d rather be able on it. At least try it, and... if I die, I die.”*
258 *(ID 17)*

259
260 Costs, insurance coverage, and logistical hurdles also influenced willingness to pursue
261 treatment. Some felt that infusions every two weeks would not affect their lifestyle, while others
262 found this disruptive. People with AD likened the logistics of anti-amyloid mAbs to receiving
263 chemotherapy for cancer.

264
265 *“It also goes with a medication that caused you to lose what you already have as far as*
266 *your physicalness, your aliveness, those kinds of things. So if it’s a medication that’s*
267 *going to maybe give you longer memory, but less life, that would make a difference.” (ID*
268 *25)*

269
270 Family also influenced how people with AD weighed side effects and costs. Some described
271 family members as being very supportive, while others described hesitation. Those whose
272 desire for treatment conflicted with family members reminded them of their autonomy despite
273 their declining cognition and again drew comparisons to cancer to address concerns. A few
274 equated forgoing treatment with unnecessarily burdening family.

275 *“My [relative] has been wonderful about it. I think he has more worries about the risks*
276 *than I do, partly because he’s like, ‘I’d rather have you even if you don’t know who I am*
277 *anymore. I’d rather have you as long as I can.’” (ID2)*

278 People with AD voiced trust in expertise and felt that the medical team took their individualized
279 risk and benefit into account. Faith in the drug approval process and their healthcare system
280 also influenced decision-making.

281
282 *“I know that no doctor is perfect. I do honestly believe that they know a lot more about*
283 *this than I do—in many ways. And I trust that they’re very, very good. And that’s the only*
284 *way I know how to answer...I don’t even think about it because I trust it. Unless*
285 *something went wrong, then it might change... It’s like I say, I feel like something*
286 *happens that makes me lose that trust. That’s hard to get back.” (ID 10)*

287
288 People with AD described a sense of pressure to accept treatment. Pressure came from family
289 members, clinicians, or a sense of personal urgency to act now (versus waiting until they may
290 not have a choice).

291
292 *“I suppose I could wait later, but I also feel like the damage that is happening, I know at*
293 *some point—I don’t wanna get to the point where I don’t have the choice anymore,*
294 *right?” (ID 2)*

295 When making a final treatment decision, a small proportion indicated that they would decide
296 alone, and a small proportion would make a group decision with family. The majority described
297 gathering input from physicians and family but ultimately felt that the decision was theirs to
298 make.

299
300 *“I will decide on my own—with agreement from the doctor. I’m certainly willing to listen to*
301 *any concerns from my family member, but ultimately it is my body, my decision.” (ID 5)*
302

303 **Ideal future state of knowledge and decision-making**

304 We also synthesized information that people with AD wanted to improve their knowledge and
305 decision-making (**Table 3**).

306 **Discussion**

307
308 To our knowledge, this is the first study evaluating how people with AD understand and
309 deliberate about anti-amyloid mAb treatment (**Figure 1**). People with AD sought out information
310 to supplement knowledge from their physicians. They hoped that state-of-the-art treatment
311 would forestall inexorable cognitive decline and bridge to more effective treatments. They were
312 motivated by taking action that could buy more time, rather than passively letting nature take its
313 course. Diminished quality of life due to side effects, costs and burdens of treatment were
314 concerns. How people with AD balanced these tradeoffs was determined by personality, family,
315 and confidence in expertise.

316 Our findings help clarify a new stage in the dementia disease trajectory: decisions about
317 disease-modifying therapy. Before effective therapies were developed, qualitative studies in
318 people with AD focused on experiences and end-of-life care. Our findings have some
319 similarities, including a shared desire for greater guidance from clinicians on expected disease
320 course. Distinct from our findings, participants in prior studies focused on behavioral (versus
321 pharmacologic) interventions and the need for more palliative care.^{18–21} Research examining
322 decision-making for people with dementia focuses on moving to a nursing home and advance
323 care planning. Some key facets overlap with our findings, like variation in perceptions of risks
324 and benefits, emotional complexity, and desire for autonomy.^{22,23} In a recent systematic review
325 of 13 qualitative studies, true decisional autonomy was rare and confined to minor decisions,
326 whereas it was nearly universal in our population with mild symptoms.²⁴

327
328 These results reveal the sensitivity and skill with which clinicians caring for people with
329 dementia must approach conversations about treatment. Our results inform how communication
330 strategies could be adapted for this need. Some participants had misconceptions about
331 lecanemab’s benefits, and potential side effects were considered minor. Given the gravity of a
332 dementia diagnosis, expressions of “unrealistic hope” may reflect normal coping or a lack of
333 cognitive understanding.^{25,26} Some clinicians may be prone to overstating benefits and
334 minimizing harms, while others focus on potential adverse sequelae.²⁷ Our results also
335 underscore the salience and complexity of emotions in treatment decisions for people with AD,
336 such as grief over loss of identity and worries about burdening family. Evidence-based
337 communication training could address these needs, including sharing personalized risks and
338 benefits, naming uncertainty, using pictorials, creating space for questions, partnering in
339 decision-making, and using empathy.^{28–32}

340
341 Our findings also highlight that promoting informed decisions about anti-amyloid mAbs would
342 benefit from incorporating messaging channels outside the clinic. External resources were
343 important for people with AD. Heightened media attention to anti-amyloid mAbs may have led to
344 passive exposure.^{33–35} Alternative resources may also have filled a vacuum while awaiting
345 subspecialty appointments or when incomplete information was provided by clinicians, a
346 phenomenon seen previously in dementia.¹⁸ Interestingly, no people with AD reported hearing
347 about lecanemab through direct-to-consumer marketing, which is both common and can distort
348 decision-making.^{36,37} Given patients' multiple streams of information, interventions to provide
349 education and decision-making support should use various modalities and start before and
350 continue after interaction with the healthcare system.

351 Patient-drawn parallels between lecanemab and chemotherapy raise potential opportunities to
352 learn from oncology care models. This comparison is apt given the rapid transformation of AD
353 care into a landscape not unlike oncology care. People with dementia who might previously
354 have felt stigmatized and hopeless about their diagnosis may now identify with cancer patients
355 who often have access to effective therapies and are valorized for their bravery.³⁸ Clinicians
356 caring for people with memory loss must now add responsibilities that are common among
357 oncologists like in-depth side effect monitoring.³⁹ Healthcare systems must now provide services
358 common in oncology care, including helping people with dementia navigate complicated visit
359 schedules. These commonalities suggest that oncology models could be adapted to support
360 people with dementia, clinicians and healthcare systems in making informed, cost-conscious
361 and goal-concordant decisions about anti-amyloid mAbs.^{40,41}

362 **Limitations**

363 Our participants had some of the earliest access to anti-amyloid mAbs. These early adopters
364 may not reflect all people with AD. For example, we identified consistent themes of self-efficacy,
365 autonomy, and eagerness to start. Our findings could simply be interpreted as natural
366 enthusiasm in response to relief from a devastating—and previously unmodifiable—diagnosis.
367 Additionally, aspects of decision-making overlapped with those in previous studies in dementia,
368 suggesting broader relevance.^{18–21} Our sample lacked racial and ethnic diversity. This is broadly
369 in line with the population characteristics at memory care clinics.⁴² Our participants exhibited
370 more educational, income and geographic diversity. Subsequent studies should examine
371 whether our findings apply in settings with greater diversity. Moreover, this should serve as a
372 call to action to improve equity in access, as we could only recruit from the subset of people
373 referred for treatment consideration.

374 **Conclusions**

375 In this first qualitative study of front-line people with dementia considering treatment with anti-
376 amyloid mAbs, we found variation in hopes for treatment, information sought and obtained, and
377 contextual factors in decision-making, supporting the need for an individualized approach.
378 Identifying these features can help identify targets for interventions to improve individualized
379 decision-making for anti-amyloid mAb treatment.

381 **Tables and Figures**

382 **Table 1 Patient Characteristics**

383
384
385

Characteristic

N=22

| Characteristic | N=22 |
|---|-------------|
| Age, mean (SD) | 70 (10) |
| Institution, n (%) | |
| Massachusetts General Hospital | 12 (55%) |
| University of Utah | 10 (45%) |
| Gender n (%) | |
| Male | 14 (64%) |
| Female | 8 (36%) |
| Orientation n (%) | |
| Heterosexual or straight | 22 (100%) |
| Race n (%) | |
| White | 22 (100%) |
| Ethnicity n (%) | |
| Non-Hispanic | 22 (100%) |
| Geographic Location n (%) | |
| Suburban | 14 (64%) |
| Rural | 6 (27%) |
| Urban | 2 (9.1%) |
| Religious Affiliation n (%) | |
| Christian | 16 (73%) |
| Agnostic | 3 (14%) |
| Atheist | 1 (4.5%) |
| Buddhist | 1 (4.5%) |
| Prefer not to answer | 1 (4.5%) |
| Highest level of education obtained n (%) | |

| Characteristic | N=22 |
|---|----------|
| High School | 1 (4.5%) |
| Some college | 5 (23%) |
| Associate's Degree | 2 (9.1%) |
| Bachelor's Degree | 7 (32%) |
| Master's Degree | 4 (18%) |
| Doctorate Degree | 3 (14%) |
| Household Income n (%) | |
| \$30,000-59,999 | 1 (4.5%) |
| \$60,000-99,999 | 7 (32%) |
| \$100,000 or more | 8 (36%) |
| Unsure/No Income | 6 (27%) |
| How ready do you feel to decide about treatment n (%) | |
| Ready to make a decision | 12 (55%) |
| Ready to make a decision but has more questions | 5 (23%) |
| Not ready to make a decision | 5 (23%) |
| If you had to decide today about treatment n (%) | |
| Yes to treatment | 15 (68%) |
| Not sure, need more information | 4 (18%) |
| No to treatment | 3 (14%) |

386

387

Table 2 Additional Illustrative Quotations from People with AD by Theme

| Theme | Illustrative quotation |
|--|------------------------|
| People with AD sought and obtained information from different sources | |

| Theme | Illustrative quotation |
|---|---|
| Advocacy organizations, the Internet and the media as resources for self-study | <i>"I think we went to the conference in [city] the year before. And that was when they were going through the approval process and that was a big focus of the conference, so that pretty much made me more aware... it was kind of emphasizing how this was a new avenue to explore. And so that's what got me interested." (ID 12)</i> |
| Variably detailed information from clinicians | <i>"It wasn't until our local doctor here gave us a whole fistful, this little stack of articles that described what it was and how it worked and what are the complications, and what are some of the things that would make it difficult for me, like the distance. It was like an article from The New England Journal of Medicine and one from the American Medical Association. He's one of these people that really keeps on top of things. I mean they were legitimate articles. Because he has access to all that kind of information through his—he's a [medical professional]." (ID 15)</i> |
| Motivating interactions with treated patients and informed family members | <i>"Our [family member] is... a [medical professional]. He runs the tests and all this, exactly this, but with younger people. And he's been very helpful with phone calls and his network that he's got fairly wide, going to conferences and things, talking with people. And has been instrumental." (ID 25)</i> |
| Hopes, expected benefits, and the existential threat of dementia driving willingness and readiness to start anti-amyloid mAbs. | |
| Stalling, reversal or cure of cognitive decline | <i>"Obviously the hope is that it can stall this disease. At least I'd feel better if they could give us some kind of parameters around... You know, for somebody with your subtype, you know, what we're seeing thus far, it can stall it two years, three years." (ID 5)</i> |
| Optimism drawn from mechanism of action and novelty compared to non-pharmacologic options | <i>"I think the biggest selling point was this is the best there is. Nothing any better and this is the way we have to go, or should go, and I was all for that." (ID 24)</i> |
| Stopgap until more effective therapy | <i>"I just made the decision that, for me, not only because of the immediacy of the potential help from lecanemab, but I don't know what's gonna happen in the future... hopefully, this gives me more time to see if something else happens as well." (ID 2)</i> |
| Motivated by desire to buy time for enjoyable activities, preserve independence, and do "something" vs nothing | <i>"I feel like I could manage going forward with the capabilities that I've retained thus far to function fairly independently if needed. So, I'm in a good spot, so if we can stop it in its tracks, that would be wonderful." (ID 5)</i> |

| Theme | Illustrative quotation |
|---|--|
| Individual traits and preferences, family factors, degree of trust in expertise influence, and sense of pressure or urgency influenced how people with AD balance risks and benefits in decision-making. | |
| Impact of personality | <i>“I have the ability to pass over the negativity a bit. So my answer to that is I—when the negatives came up, I didn't listen very well...I think I kind of passed over it. I was really centered on the idea that I was going to get better. I let the rest—if there was any rest, I let it fly by. You know, being a man [in their 80's] who is cognitively challenged is not all bad. You're kind of a funny old bastard wandering through life. And I kind of like being that. It's not that bad.” (ID 16)</i> |
| Perceived inevitability of decline | <i>“What do I have to lose? Is basically the way I look at it. I mean, even if it does cause problems for me, I'm headed that way already...might be a different kind of problem. I don't care.”(ID 10)</i> |
| Weighing side effects, costs and logistical burdens | <i>“Well, the biggest drawback is how much it's gonna cost. I don't know if I can afford it. My understanding was that there would be some, but I don't know what the price is and the cost—out of pocket. That will make—that's-that's a stop right there, if it's too high...That to me is the only thing that will possibly stop.” (ID 10)</i> |
| Importance of supportive families | <i>“How I rationalize that in my mind and then turn around and had a conversation with my husband, I said, ‘If I had breast cancer, nobody would question if I was going for chemotherapy tomorrow, but technically chemotherapy is a poison.’ And at some point long before we became conditioned to hearing about chemotherapy, it sounded big, bad, and scary too... once I kind of laid that scenario out about the chemotherapy, I think it kind of put everything into perspective and nobody's really said anything negative since.” (ID 5)</i> |
| Trust in expertise | <i>“I feel, I gotta think the FDA has done its job. Like I think that you guys are, you know, have one of the-the best hospitals in the world and the best doctors. So if you're gonna have this disease, I think I have it at the right place with the right hospital, with the right doctors, with the right partner.” (ID 12)</i> |
| Family and physicians as sources of pressure | <i>“I kinda got the impression that he [the physician] was recommending it or that it would give me more years. Pushing it's too strong a word, but that he was encouraging it in some way... I got the impression he was definitely pro doing the drugs. I don't know if that's based on good results he's seen in patients or whether it's just kinda the latest thing to try. The latest thing to do.” (ID 15)</i> |

| Theme | Illustrative quotation |
|---|---|
| Making calculated risks and conscious tradeoffs | <i>I'm ready to do it, willing to do it...Is it a perfect world? Not always. But I'm fine with that. Calculated risk.” (ID 8)</i> |
| Sense of urgency to decide | <i>“I'm ready. ‘Cause I feel like the longer it takes, I feel like I lose more cognitive abilities. And so I'm anxious to get started in the hopes that this will slow everything down. Because once you lose what you lose, you don't get it back.” (ID 6)</i> |
| Autonomy | <i>“I think it's a combination of two things. I'd like to talk to the doctor to understand what he or she knows and take that information with the family and say listen, there's no guarantees. But I honestly think that my family would say, ‘Go for it.’ Got nothin' to lose, really, in a sense.” (ID 8)</i> |

388

389

Table 3: Desired information and support for anti-amyloid mAb treatment decisions

| Desired information and support | Representative quotation |
|---|---|
| Personalized information on benefits | <i>“I need to know what the results of other patients are. And preferably other patients that fit my same general condition, age, that kind of stuff...” (ID 26)</i> |
| Personalized information on risks | <i>“Obviously, I wanna know how prevalent the bad side effects are. If it's a little discomfort on getting the infusion, that's not a problem. The things that I'm concerned about are the things that would either make it far worse or sooner than letting it run its course.” (ID 3)</i> |
| Detailed and personalized information on ARIA-H and its treatments | <i>“That sounds pretty drastic. It could be. I'd wanna know more about why... And if there can be blood in the brain, you know, is that—do I need an operation to get that fixed? Am I gonna die, or will that—is that normal? (ID 18)</i> |
| Updates on long-term outcomes from patients in the trials | <i>“I read about the studies and the results of their initial trials, but I guess I don't know if there's been any documentation or anywhere I should look for follow up information on what's been learned now to date. Not just from the initial study but what's been learned from circling back to those original patients. Like is it still stalled or did they have to do another course?” (ID 5)</i> |
| Testimonials from people with AD to give a “human face” to statistics | <i>“But in terms of, just kind of on a daily basis how it would help you out or not help you out. Not just the—'cause the-the stuff we read was all like statistics on, you know, improved this for so many months or weeks or a year or whatever. There was nothing personal about how people who've taken it actually reacted to it and how they felt about it.” (ID 15)</i> |
| Handout | <i>“Is there-are there papers? I don't wanna read all the big papers.”</i> |

Desired information and support Representative quotation

But like is there a one or two side paper or something? It would be nice to have something like that from the doctors not the drug company.” (ID 4)

Website

“A website? You mean, like, that’ll give me information? Yeah. That would be helpful. Maybe to reassure——the information, I guess, is the best.” (ID 17)

390

391

Figure 1 Major Themes, Subthemes and Implications Identified in People with AD Undergoing Evaluation for Lecanemab Treatment

392

393

394

395

References

396

397

398

399

400

1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease. *New England Journal of Medicine*. Massachusetts Medical Society; 2023 Jan 5;388(1):9–21. PMID: 36449413

401

402

2. Yadollahikhales G, Rojas JC. Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update. *Neurotherapeutics*. 2023 Jul;20(4):914–931. PMID: PMC10457266

403

404

405

406

407

408

3. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. *Alzheimers Dement*. 2011 Jul;7(4):367–385. PMID: PMC3693547

409

410

411

4. Ko D, Pascual-Leone A, Shah SJ. Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty. *JAMA [Internet]*. 2024 Mar 15 [cited 2024 Mar 27]; Available from: <https://doi.org/10.1001/jama.2024.2991>

412

413

414

5. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis*. 2023;10(3):362–377. PMID: PMC10313141

415

416

417

6. Arbanas JC, Damberg CL, Leng M, Harawa N, Sarkisian CA, Landon BE, Mafi JN. Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program. *JAMA Intern Med*. 2023 Aug 1;183(8):885–889. PMID: PMC10176174

418

419

7. Widera EW, Brangman SA, Chin NA. Ushering in a New Era of Alzheimer Disease Therapy. *JAMA*. 2023 Aug 8;330(6):503–504.

420

421

422

8. Sarkisian CA, Romanov A, Mafi JN. Talking With Patients About the New Anti-amyloid Alzheimer Disease Medications. *Ann Intern Med*. American College of Physicians; 2024 Feb 20;177(2):246–248.

- 423 9. Chin NA, Widera E, Brangman SA, Karlawish J. Monoclonal anti-amyloid antibodies for the
424 treatment of Alzheimer’s disease and the hesitant geriatrician. *Journal of the American*
425 *Geriatrics Society*. 2024;72(2):643–645.
- 426 10. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision
427 making and patient outcomes. *Med Decis Making*. 2015 Jan;35(1):114–131. PMID:
428 PMC4270851
- 429 11. Stacey D, Légaré F, Boland L, Lewis KB, Loiselle MC, Hoefel L, Garvelink M, O’Connor A.
430 20th Anniversary Ottawa Decision Support Framework: Part 3 Overview of Systematic
431 Reviews and Updated Framework. *Med Decis Making*. 2020 Apr;40(3):379–398. PMID:
432 32428429
- 433 12. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
434 (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for*
435 *Quality in Health Care*. 2007 Dec 1;19(6):349–357.
- 436 13. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications
437 for conducting a qualitative descriptive study. *Nurs Health Sci*. 2013 Sep;15(3):398–405.
438 PMID: 23480423
- 439 14. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in*
440 *Psychology*. Routledge; 2006 Jan 1;3(2):77–101.
- 441 15. Malterud K, Siersma VD, Guassora AD. Sample Size in Qualitative Interview Studies:
442 Guided by Information Power. *Qual Health Res*. 2016 Nov;26(13):1753–1760. PMID:
443 26613970
- 444 16. Hennink MM, Kaiser BN, Marconi VC. Code Saturation Versus Meaning Saturation: How
445 Many Interviews Are Enough? *Qual Health Res*. 2017 Mar;27(4):591–608. PMID:
446 PMC9359070
- 447 17. What is an adequate sample size? Operationalising data saturation for theory-based
448 interview studies - PubMed [Internet]. [cited 2024 Jul 11]. Available from:
449 <https://pubmed.ncbi.nlm.nih.gov/20204937/>
- 450 18. Shafir A, Ritchie CS, Garrett SB, Sideman AB, Naasan G, Merrilees J, Widera E, Flint L,
451 Harrison KL. “Captive by the uncertainty” – Experiences with anticipatory guidance for
452 people living with dementia and their caregivers at a specialty dementia clinic. *J*
453 *Alzheimers Dis*. 2022;86(2):787–800. PMID: PMC9717709
- 454 19. Harrison KL, Garrett SB, Halim M, Sideman AB, Allison TA, Dohan D, Naasan G, Miller BL,
455 Smith AK, Ritchie CS. “I didn’t sign up for this”: perspectives from persons living with
456 dementia and care partners on challenges, supports, and opportunities to add geriatric
457 neuropsychiatric care to dementia specialty care. *J Alzheimers Dis*. 2022;90(3):1301–1320.
458 PMID: PMC9712265
- 459 20. Bunn F, Goodman C, Sworn K, Rait G, Brayne C, Robinson L, McNeilly E, Iliffe S.
460 Psychosocial Factors That Shape Patient and Carer Experiences of Dementia Diagnosis
461 and Treatment: A Systematic Review of Qualitative Studies. *PLoS Med*. 2012 Oct
462 30;9(10):e1001331. PMID: PMC3484131

- 463 21. Prorok JC, Horgan S, Seitz DP. Health care experiences of people with dementia and their
464 caregivers: a meta-ethnographic analysis of qualitative studies. *CMAJ*. 2013 Oct
465 1;185(14):E669–E680. PMID: PMC3787191
- 466 22. Young JA, Lind C, Orange J. A qualitative systematic review of experiences of persons with
467 dementia regarding transition to long-term care. *Dementia*. SAGE Publications; 2021 Jan
468 1;20(1):5–27.
- 469 23. Sellars M, Chung O, Nolte L, Tong A, Pond D, Fetherstonhaugh D, McInerney F, Sinclair C,
470 Detering KM. Perspectives of people with dementia and carers on advance care planning
471 and end-of-life care: A systematic review and thematic synthesis of qualitative studies.
472 *Palliat Med*. SAGE Publications Ltd STM; 2019 Mar 1;33(3):274–290.
- 473 24. Bhatt J, Walton H, Stoner CR, Scior K, Charlesworth G. The nature of decision-making in
474 people living with dementia: a systematic review. *Aging & Mental Health*. Routledge; 2020
475 Mar 3;24(3):363–373.
- 476 25. Patients' Expectations of the Benefits and Harms of Treatments, Screening, and Tests: A
477 Systematic Review | Nursing | JAMA Internal Medicine | JAMA Network [Internet]. [cited
478 2024 Jun 12]. Available from:
479 <https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2038981>
- 480 26. Brenner K, Greer JA, Jackson V, Park E, Wright E, Jacobsen J, Topping C, Jagielo A,
481 Elyze M, Sereno I, Temel JS, El-Jawahri A. Development of a Prognostic Awareness
482 Impact Scale for Patients with Advanced Cancer. *J Palliat Med*. 2022 Mar;25(3):445–454.
483 PMID: 34637630
- 484 27. Morgan DJ, Pineles L, Owczarzak J, Magder L, Scherer L, Brown JP, Pfeiffer C, Terndrup
485 C, Leykum L, Feldstein D, Foy A, Stevens D, Koch C, Masnick M, Weisenberg S,
486 Korenstein D. Clinician Conceptualization of the Benefits of Treatments for Individual
487 Patients. *JAMA Network Open*. 2021 Jul 21;4(7):e2119747.
- 488 28. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care.
489 *N Engl J Med*. 2012 Mar 1;366(9):780–781. PMID: 22375967
- 490 29. Dahm MR, Cattanach W, Williams M, Basseal JM, Gleason K, Crock C. Communication of
491 Diagnostic Uncertainty in Primary Care and Its Impact on Patient Experience: an
492 Integrative Systematic Review. *J Gen Intern Med*. 2023 Feb;38(3):738–754. PMID:
493 PMC9971421
- 494 30. Paladino J, Bernacki R, Neville BA, Kavanagh J, Miranda SP, Palmor M, Lakin J, Desai M,
495 Lamas D, Sanders JJ, Gass J, Henrich N, Lipsitz S, Fromme E, Gawande AA, Block SD.
496 Evaluating an Intervention to Improve Communication Between Oncology Clinicians and
497 Patients With Life-Limiting Cancer: A Cluster Randomized Clinical Trial of the Serious
498 Illness Care Program. *JAMA Oncol*. 2019 Jun 1;5(6):801–809. PMID: 30870556
- 499 31. Paladino J, Koritsanszky L, Nisotel L, Neville BA, Miller K, Sanders J, Benjamin E, Fromme
500 E, Block S, Bernacki R. Patient and clinician experience of a serious illness conversation
501 guide in oncology: A descriptive analysis. *Cancer Med*. 2020 May 4;9(13):4550–4560.
502 PMID: PMC7333843

- 503 32. Braddock CH, Edwards KA, Hasenberg NM, Laidley TL, Levinson W. Informed decision
504 making in outpatient practice: time to get back to basics. *JAMA*. 1999 Dec
505 22;282(24):2313–2320. PMID: 10612318
- 506 33. Allen A. The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will
507 foot much of the bill - CBS News [Internet]. 2023 [cited 2024 Jun 12]. Available from:
508 <https://www.cbsnews.com/news/alzheimers-drug-leqembi-cost-patients-taxpayers/>
- 509 34. Leqembi and Alzheimer’s: What to Know About the New Drug, Treatment and Benefits -
510 The New York Times [Internet]. [cited 2024 Jun 12]. Available from:
511 <https://www.nytimes.com/2024/06/10/well/mind/alzheimers-treatment-leqembi.html>
- 512 35. J, o, n, H, a, m, i, l, t, o, n. An experimental Alzheimer’s drug outperforms one just
513 approved by the FDA. NPR [Internet]. 2023 Jul 17 [cited 2024 Jun 12]; Available from:
514 [https://www.npr.org/sections/health-shots/2023/07/17/1188075646/donanemab-](https://www.npr.org/sections/health-shots/2023/07/17/1188075646/donanemab-experimental-alzheimers-drug-outperforms-lecanemab-leqembi)
515 [experimental-alzheimers-drug-outperforms-lecanemab-leqembi](https://www.npr.org/sections/health-shots/2023/07/17/1188075646/donanemab-experimental-alzheimers-drug-outperforms-lecanemab-leqembi)
- 516 36. Schwartz LM, Woloshin S. Medical Marketing in the United States, 1997-2016. *JAMA*.
517 2019 Jan 1;321(1):80–96.
- 518 37. O’Donoghue AC, Johnson M, Sullivan HW, Parvanta S, Ray S, Southwell BG. Aging and
519 Direct-to-Consumer Prescription Drug Television Ads: The Effects of Individual Differences
520 and Risk Presentation. *Journal of Health Communication*. Taylor & Francis; 2019 Apr
521 3;24(4):368–376.
- 522 38. Robb KA, Simon AE, Miles A, Wardle J. Public perceptions of cancer: a qualitative study of
523 the balance of positive and negative beliefs. *BMJ Open*. 2014 Jul 10;4(7):e005434.
524 PMID: PMC4120326
- 525 39. Garrett SB, Matthews TM, Abramson CM, Koenig CJ, Hlubocky FJ, Daugherty CK,
526 Munster PN, Dohan D. Before Consent: Qualitative Analysis of Deliberations of Patients
527 With Advanced Cancer About Early-Phase Clinical Trials. *JCO Oncol Pract*. 2020
528 Jan;16(1):e56–e63. PMID: PMC6993554
- 529 40. Shickh S, Leventakos K, Lewis MA, Bombard Y, Montori VM. Shared Decision Making in
530 the Care of Patients With Cancer. *Am Soc Clin Oncol Educ Book*. Wolters Kluwer; 2023
531 Jun;(43):e389516.
- 532 41. Henrikson NB, Shankaran V. Improving Price Transparency in Cancer Care. *J Oncol Pract*.
533 2016 Jan;12(1):44–47. PMID: 26759467
- 534 42. Boyd ND, Naasan G, Harrison KL, Garrett SB, D’Aguiar Rosa T, Pérez-Cerpa B,
535 McFarlane S, Miller BL, Ritchie CS. Characteristics of people with dementia lost to follow-
536 up from a dementia care center. *Int J Geriatr Psychiatry*. 2022 Jan;37(1). PMID:
537 PMC8740544

538

539 **Supplement**

540

541 Appendix 1 COREQ checklist

542 Appendix 2 Master coded thematic statements

Figure 1 Major Themes, Subthemes and Implications Identified in People with AD Undergoing Evaluation for Lecanemab Treatment

| Major Themes | Subthemes | Implications |
|--|--|---|
| <p>People with dementia sought and obtained information from different sources</p> | <ul style="list-style-type: none">▪ Advocacy organizations, the Internet and the media as resources for self-study▪ Variably detailed information from clinicians▪ Motivating interactions with treated patients and informed family members | <p>Incorporate messaging approaches and channels outside the clinical encounter and healthcare system.</p> |
| <p>Hopes, expected benefits, and the existential threat of dementia driving willingness and readiness to start anti-amyloid mAbs.</p> | <ul style="list-style-type: none">▪ Stalling, reversal or cure of cognitive decline▪ Optimism drawn from mechanism of action and novelty compared to non-pharmacologic options▪ Stopgap until more effective therapy▪ Motivated by desire to buy time for enjoyable activities, preserve independence, and do "something" vs nothing | <p>Apply communication skills that balance validating the importance of hope with accurate portrayal of personalized risks and benefits.</p> |
| <p>Individual traits and preferences, family factors, and degree of trust in expertise influence how people with dementia balance risks and benefits.</p> | <ul style="list-style-type: none">▪ Impact of personality▪ Perceived inevitability of decline▪ Weighing side effects, costs and logistical burdens▪ Importance of supportive families▪ Trust in expertise▪ Family and physicians as sources of pressure▪ Making calculated risks and conscious tradeoffs▪ Sense of urgency to decide▪ Autonomy | <p>Adapt communication training that acknowledges and builds upon strong emotions.</p> <p>Capitalize on patient-identified parallels with oncology and consider adapting oncology models of care.</p> |